Samalin, E., Bouché, O., Thézenas, S., Francois, E., Adenis, A., Bennouna, J., . . . Mazard, T. (2014). Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: A multicentre Phase I/II trial. Nature Publishing Group.
Citação norma ChicagoSamalin, E., et al. Sorafenib and Irinotecan (NEXIRI) As Second- or Later-line Treatment for Patients With Metastatic Colorectal Cancer and KRAS-mutated Tumours: A Multicentre Phase I/II Trial. Nature Publishing Group, 2014.
MLA CitationSamalin, E., et al. Sorafenib and Irinotecan (NEXIRI) As Second- or Later-line Treatment for Patients With Metastatic Colorectal Cancer and KRAS-mutated Tumours: A Multicentre Phase I/II Trial. Nature Publishing Group, 2014.